Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 12/20 | 0.41 |
| ▸ | FEN1 | P39748 | 12/20 | 0.41 |
| ▸ | PARG | Q86W56 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790761 | 1.00 | NSD2 (0.45) | NSD2ALOX5APFEN1PARGMAPT | |
| SCHEMBL14328457 | 0.78 | NSD2 (0.47) | NSD2ALOX5APFEN1PARGMAPT | |
| SCHEMBL29230444 | 0.77 | HSD17B10 (0.39) | SMN1; SMN2 | |
| SCHEMBL8954157 | 0.76 | P2RY2 (0.38) | — | |
| SCHEMBL2803354 | 0.75 | NSD2 (0.58) | NSD2ALOX5APFEN1PARGMAPT | |
| SCHEMBL1792013 | 0.74 | USP30 (0.37) | NSD2ALOX5APFEN1PARGALDH1A1 | |
| SCHEMBL1792014 | 0.74 | USP30 (0.37) | NSD2ALOX5APFEN1PARGALDH1A1 | |
| SCHEMBL1790221 | 0.73 | ALDH1A1 (0.53) | PARGMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1790218 | 0.73 | ALDH1A1 (0.53) | PARGMAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL8534729 | 0.73 | NSD2 (0.49) | NSD2ALOX5APFEN1PARGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2010002998-A1 | 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, CYP2S1, DPYD | NSD2 844/4885ALOX5AP 902/4885FEN1 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.